An Efficacy Trial of The Toolkit for Optimal Recovery After Concussion (An efficacy tr)

November 10, 2026 updated by: Jonathan Greenberg, Massachusetts General Hospital

The goal of this study is to test the efficacy of the Toolkit for Optimal Recovery after Concussion (TOR-C), a brief live-video mind-body program. aiming to prevent chronic concussion symptoms and optimize recovery.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

260

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Sustained a concussion 3-10 weeks earlier
  2. At least mild anxiety symptoms (score ≥ 5 on GAD-7 anxiety scale)
  3. Age 18-35
  4. English fluency and literacy
  5. Ability and willingness to participate in study procedures, assessments, and intervention
  6. Access to a smartphone or computer with internet access
  7. Cleared for participation by clinic/study staff

Exclusion Criteria:

  1. Participation in mind-body or CBT treatment in the past 3 months
  2. Concussion in the past 2 years that resulted in symptoms lasting 3 months or more / current or previous complicated or moderate/severe TBI
  3. Practice of mindfulness techniques > 45 minutes/week in the past 3 months
  4. Change in psychotropic medications (e.g., antidepressant, anxiolytics) in the past 6 weeks
  5. Uncontrolled bipolar disorder, psychosis, active substance dependence, self reported current active suicidal ideation with plan and/or intent
  6. Pregnancy
  7. Serious comorbidity expected to worsen in the next 6 months
  8. Secondary gains that may bias motivation (e.g., pending disability claim)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Toolkit for Optimal Recovery after Concussion (TOR-C)

A 4-week mind-body program delivered via live video (Zoom) 1:1 with a clinician delivering mind-body and cognitive-behavioral skills.

TOR-C is a brief behavioral mind-body program delivered remotely via live video over four weekly 45-minute sessions, with approximately 10 minutes of daily home practice. It targets anxiety and fear-avoidance factors to prevent chronic concussion symptoms, combining mind-body skills (e.g., mindfulness, deep breathing, acceptance), light cognitive-behavioral skills, skills for gradual return to activity, and concussion psychoeducation.

Active Comparator: Health Enhancement after Concussion (HE-C)

A 4-week program delivered via live video (Zoom) 1:1 with a clinician delivering psychoeducation and information about healthy living after a concussion

HE-C is an attention-matched active control program delivered remotely via live video over four weekly 45-minute sessions, with approximately 10 minutes of daily home practice. It provides general health education after concussion (e.g., sleep, nutrition, physical activity) without the specific skills included in TOR-C.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Post-Concussion Symptom Scale (PCSS)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures the severity of concussion symptoms (e.g., headache, fatigue, dizziness, difficulty concentrating). This is the study's primary outcome; efficacy is judged mainly on reducing these symptoms.

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Generalized Anxiety Disorder scale (GAD-7)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures the severity of anxiety symptoms. (Also used at screening, where a score ≥5 is required for eligibility.)

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures the severity of depression symptoms.

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
Fear Avoidance Behavior after Traumatic Brain Injury (FAB-TBI)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures fear-avoidance behavior, i.e., avoiding activities out of fear they will worsen symptoms. A core mechanism in the fear-avoidance model.

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
Symptom Catastrophizing Scale
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures the tendency to catastrophize concussion symptoms (magnifying, ruminating on, or feeling helpless about them).

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures mindfulness, i.e., present-moment awareness and acceptance of thoughts and feelings.

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
Behavioral Response to Illness Questionnaire (BRIQ): Limiting behavior subscale
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures the tendency to limit or avoid various activities in response to medical conditions

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

An exploratory outcome which measures sleep quality over the past month.

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
PROMIS Cognitive Function
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

An exploratory outcome which measures self-reported cognitive function (e.g., perceived problems with memory, attention, and thinking).

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
WHO Disability Assessment Schedule (WHODAS 2.0; 12-item version)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

It is 12-item measure of health-related functioning and disability across daily activities (e.g., cognition, mobility, self-care, social participation) over the past 30 days, with higher scores indicating greater disability.

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2027

Primary Completion (Estimated)

December 1, 2030

Study Completion (Estimated)

December 1, 2030

Study Registration Dates

First Submitted

October 29, 2026

First Submitted That Met QC Criteria

October 29, 2026

First Posted (Actual)

November 9, 2026

Study Record Updates

Last Update Posted (Actual)

November 13, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2026P002591

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

We plan to share our study protocol, analysis plan, data dictionary, and de-identified data from all measures described under "outcome measures"

IPD Sharing Time Frame

Data from this study will be deposited into the Vivli database no later than one year of the completion of the funded project period

IPD Sharing Access Criteria

Interested parties can create an account in the Vivli Database and submit a request to access study data

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.